

Sartorius Presents Nine-month Figures

- The Biotechnology Division continues its dynamic growth and boosts profitability again
- Cost-reduction and restructuring measures take effect in the Mechatronics Division: Third-quarter operating earnings slightly positive
- Consolidated operating earnings up from a year ago

Goettingen, October 22, 2009 – Today Sartorius, a leading international process and laboratory technology provider, reported its nine-month results for 2009. Third-quarter business of both Group divisions showed a highly divergent pattern of development, similar to that in the previous quarters. While the Biotechnology Division achieved strong sales gains and overproportionate increases in earnings, development in the Mechatronics Division continued to be considerably impacted by the global downturn. However, the latter division's second- and third-quarter order intake and sales stabilized at a lower level. Due to the extensive cost-saving measures implemented, operating earnings of the Mechatronics Division moved back into the profit zone in the third quarter.

Business Development of the Divisions

Sartorius Stedim Biotech

The Biotechnology Division (Sartorius Stedim Biotech/SSB), which contributes approx. two-thirds to consolidated sales, was able to continue its dynamic growth trend into the third quarter of 2009 as well. After nine months of business activity, its order intake was at 303.4 million euros and thus up 12.7% from a year ago (currency-adjusted: 10.3%). Again, business with single-use products fueled this increase by generating strong double-digit growth rates. In addition to its already positive development, Sartorius Stedim Biotech profited from the strong demand generated by its customers from the vaccine industry. By contrast, business with large-scale bioreactor systems declined slightly due to market conditions. Considering sales revenue, the Biotechnology Division also posted sizeable gains. In the reporting period, its sales climbed 9.0% (currency-adjusted: 6.7%) from 273.3 million euros a year earlier to 298.0 million euros. All business regions with their significantly positive growth rates contributed to the successful development of sales.

This strong sales development is also reflected by the Biotechnology Division's nine-month earnings. Operating earnings (earnings before interest, taxes and amortization and adjusted for extraordinary expenses = underlying EBITA) showed significantly overproportionate improvement, surging 58.9% to 46.3 million euros. In the year-earlier period, they were at 29.1 million euros. The corresponding margin rose from 10.7% to 15.5% in the current reporting period. Besides the uplift in sales volume, the Biotechnology Division's enhanced product mix favoring high-margin single-use products especially contributed to this surge in profitability.

"The earnings of Sartorius Stedim Biotech impressively show that we are on the right track with our business strategy and our product portfolio," commented Sartorius CEO Joachim Kreuzburg. "For our customers in the biopharmaceutical industry, we are now excellently positioned as a total solution provider with a high proportion of innovative single-use products."

Sartorius Mechatronics

The Mechatronics Division continued to be heavily impacted by the global downturn. In the reporting period, the division received orders valued at 151.4 million euros. In comparison with the year-ago figure, order intake thus fell 18.0% (currency-adjusted: -20.6%). In the second and third quarters, this decline hit industrial weighing equipment business particularly hard, but laboratory business also substantially contracted. By contrast, service business showed relatively stable development. Sales revenue reported by the Mechatronics Division fell 18.5% from 180.0 million euros a year ago to 146.8 million euros (currency-adjusted: -21.1%). The regional pattern shows that the division's decline in revenue was less pronounced for Asia/Pacific than for Europe and North America.

Nine-month operating earnings for the Mechatronics Division was -2.4 million euros (Q1-Q3 2008: 11.4 million euros) as a result of the drop in sales. Following losses in the first and second quarters of the current year, the division reported slightly positive operating earnings in the third quarter. This was due to cost-reduction measures that have already been implemented for the most part.

The Mechatronics Division has extended its package of cost-cutting and restructuring measures for the Mechatronics Division. Its target is to achieve a sustainable reduction in its annual cost base by more than 30 million euros (so far more than 25 million euros). This program is targeted at reducing approximately 250 positions. The majority of the division's cost-cutting measures were completed in the third quarter.

"The cutbacks in the Mechatronics Division are painful, but essential, in order to reverse the effects of the global recession on our company and to create a stable starting position for ourselves in this division for the future," said Joachim Kreuzburg. "Now that we are nearing successful completion of our cost-reduction program, we will focus fully on the further development of our strategic positioning and on tapping into additional business segments in Mechatronics."

Business Development of the Sartorius Group

At the Group level, order intake at 454.8 million euros attained the year-earlier level of 454.0 million euros (+0.2%; currency-adjusted: -2.3%). Nine-month consolidated sales revenue was 444.7 million euros compared with 453.4 million euros a year ago, and therefore eased 1.9% (currency-adjusted: -4.3%) relative to the year-earlier period. Regarding consolidated operating earnings, strong development in the Biotechnology Division compensated for the weak earnings contribution in Mechatronics, which was due to the recession: Operating earnings rose from 40.6 million euros to 43.9 million euros.

The corresponding margin increased from 8.9% to 9.9%. Extraordinary expenses totaled 24.7 million euros, which essentially entail provisions for the restructuring program already implemented in the Mechatronics Division to a large extent. Unadjusted consolidated EBITA was 19.2 million euros (Q1–Q3 2008: 40.6 million euros).

Without the two non-cash items of amortization and interest for share price warrants, consolidated underlying net profit after minority interest was at 13.9 million euros, up from 13.7 million euros a year earlier; the corresponding earnings per share were at 0.81 euro, up from 0.80 euro in the previous year.

Outlook

For the last three months of the current fiscal year, company management expects the Biotechnology Division's revenue to increase and its earnings to rise overproportionately relative to the fourth quarter in 2008. The company continues to expect exceptionally difficult market conditions for the Mechatronics Division. However, management anticipates a slightly positive fourth-quarter underlying EBITA for this division because of its successfully implemented cost-reduction program.

Current Image Files:

Joachim Kreuzburg, CEO of Sartorius:

http://www.sartorius.com/media/content/press/support/Dr_Kreuzburg_3.jpg

http://www.sartorius.com/fileadmin/Image_Archive/sartorius_media/portraits/2009_DrKreuzburg.jpg

Sartorius | Biotechnology Division (Sartorius Stedim Biotech):

http://www.sartorius.com/media/content/press/support/Sartorius_0095_PG4.jpg

Sartorius | Mechatronics Division:

http://www.sartorius.com/media/content/press/support/Mechatronics_AR_2008.jpg

Conference Call and Webcast:

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the nine-month figures with analysts and investors today, October 22, 2009, at 3:00 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 2:45 p.m. CET at the following numbers:

Germany: +49 (0)69 9897 2623

France: +33 (0)1 70 99 42 84

UK: +44 (0)20 7138 0845

USA: +1 212 444 0896

The dial-in code is: 4830253; to view the webcast, log onto: <http://www.sartorius.com>

Upcoming Financial Dates:

| | |
|----------------|--|
| February 2010 | Publication of the preliminary figures for fiscal 2009 |
| March 9, 2010 | Annual press conference in Goettingen, Germany |
| April 21, 2010 | Annual Shareholders' Meeting in Goettingen, Germany |
| April 2010 | Publication of the first-quarter figures (Jan. – March 2010) |

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties.

A Profile of Sartorius

The Sartorius Group is a leading international laboratory and process technology provider covering the segments of biotechnology and mechatronics. In 2008, the technology group earned sales revenue of 611.6 million euros. Founded in 1870, the Goettingen-based company currently employs approximately 4,450 persons. The major areas of activity in its biotechnology segment focus on fermentation, filtration, purification, fluid management and laboratory applications. In the mechatronics segment, the company primarily manufactures equipment and systems featuring weighing, measurement and automation technology for laboratory and industrial applications. Key Sartorius customers are from the pharmaceutical, chemical and food and beverage industries and from numerous research and educational institutes of the public sector. Sartorius has its own production facilities in Europe, Asia and America as well as sales subsidiaries and local commercial agencies in more than 110 countries.

Contact:

Petra Kirchhoff, Vice President of Group Corporate Communications
Sartorius Corporate Administration GmbH; 37070 Goettingen, Germany
Phone: +49 (0)551/ 308-1686
Fax: +49 (0)551/ 308-3572
E-mail: petra.kirchhoff@sartorius.com
www.sartorius.com